Effectiveness of COVID-19 vaccine BNT162b2 at age 12-15 years with one dose‏

Nadav Davidovitch; Oren Miron; Rachel Wilf-Miron

doi:10.31219/osf.io/cnw5t

Effectiveness of COVID-19 vaccine BNT162b2 at age 12-15 years with one dose‏

Nadav Davidovitch, Oren Miron, Rachel Wilf-Miron

Department of Health Policy and Management

Ben-Gurion University of the Negev

Research output: Working paper › Preprint

Abstract

The clinical trial of BNT162b2 at age 12-15 years reported 100% effectiveness in preventing COVID-19 after 7 days from dose-2, which is administrated at day 21. We reanalyzed the data and found 100% effectiveness also after 14-20 days from dose-1 administration. This could relate to studies showing increased dose-1 effectiveness at younger ages. Our findings support the possibility of vaccinating younger ages with the United Kingdom regimen, which delays dose-2 to day 84 to allow more dose-1 vaccinations.

Original language	American English
DOIs	https://doi.org/10.31219/osf.io/cnw5t
State	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.31219/osf.io/cnw5t

Cite this

@techreport{2cbb9fbf9d6446fbbdb19ee06b9e45da,

title = "Effectiveness of COVID-19 vaccine BNT162b2 at age 12-15 years with one dose‏",

abstract = "The clinical trial of BNT162b2 at age 12-15 years reported 100% effectiveness in preventing COVID-19 after 7 days from dose-2, which is administrated at day 21. We reanalyzed the data and found 100% effectiveness also after 14-20 days from dose-1 administration. This could relate to studies showing increased dose-1 effectiveness at younger ages. Our findings support the possibility of vaccinating younger ages with the United Kingdom regimen, which delays dose-2 to day 84 to allow more dose-1 vaccinations.",

author = "Nadav Davidovitch and Oren Miron and Rachel Wilf-Miron",

year = "2021",

doi = "10.31219/osf.io/cnw5t",

language = "American English",

type = "WorkingPaper",

}

TY - UNPB

T1 - Effectiveness of COVID-19 vaccine BNT162b2 at age 12-15 years with one dose‏

AU - Davidovitch, Nadav

AU - Miron, Oren

AU - Wilf-Miron, Rachel

PY - 2021

Y1 - 2021

N2 - The clinical trial of BNT162b2 at age 12-15 years reported 100% effectiveness in preventing COVID-19 after 7 days from dose-2, which is administrated at day 21. We reanalyzed the data and found 100% effectiveness also after 14-20 days from dose-1 administration. This could relate to studies showing increased dose-1 effectiveness at younger ages. Our findings support the possibility of vaccinating younger ages with the United Kingdom regimen, which delays dose-2 to day 84 to allow more dose-1 vaccinations.

AB - The clinical trial of BNT162b2 at age 12-15 years reported 100% effectiveness in preventing COVID-19 after 7 days from dose-2, which is administrated at day 21. We reanalyzed the data and found 100% effectiveness also after 14-20 days from dose-1 administration. This could relate to studies showing increased dose-1 effectiveness at younger ages. Our findings support the possibility of vaccinating younger ages with the United Kingdom regimen, which delays dose-2 to day 84 to allow more dose-1 vaccinations.

U2 - 10.31219/osf.io/cnw5t

DO - 10.31219/osf.io/cnw5t

M3 - Preprint

BT - Effectiveness of COVID-19 vaccine BNT162b2 at age 12-15 years with one dose‏

ER -

Effectiveness of COVID-19 vaccine BNT162b2 at age 12-15 years with one dose‏

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this